^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

TrkC kinase inhibitor

12ms
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
taletrectinib (AB-106)
1year
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
1year
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • NTRK3 positive • NTRK fusion
over1year
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • NTRK3 positive • NTRK fusion
over1year
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 fusion
|
Xalkori (crizotinib) • Rozlytrek (entrectinib)
over1year
Preclinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK3 fusion • RET fusion • RET positive • NTRK fusion
|
Retevmo (selpercatinib)
over1year
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • ETV6-NTRK3 fusion
over1year
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
taletrectinib (AB-106)
over1year
MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
MET amplification
|
Rozlytrek (entrectinib)
over1year
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
over1year
Preclinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK3 fusion • RET fusion • RET positive • NTRK fusion
|
Retevmo (selpercatinib)
over1year
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
taletrectinib (AB-106)
over1year
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
over1year
Preclinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK3 fusion • RET fusion • RET positive • NTRK fusion
|
Retevmo (selpercatinib)
almost2years
Circulating tumor DNA
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
almost2years
Clinical
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Rozlytrek (entrectinib)
almost2years
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
almost2years
Clinical
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
|
NTRK3 fusion • RET fusion • RET positive
|
Retevmo (selpercatinib)
almost2years
Clinical • IO biomarker
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation
|
Xalkori (crizotinib) • Rozlytrek (entrectinib) • Zykadia (ceritinib)
almost2years
Clinical
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
ROS1 fusion • ROS1 positive • NTRK positive • NTRK fusion
|
Rozlytrek (entrectinib)